Two murine monoclonal antibodies, IIG5 (IgG3) and IVE8 (IgG2a) 
Pseudomonas aeruginosa, a gram-negative bacterium, is an opportunistic pathogen that causes significant morbidity and mortality in immunocompromised patients (9, 41, 44) . The high rate of mortality associated with P. aeruginosa infections occurs, in part, because of the resistance of the organisms to many antibiotics (7, 18) . Therefore, numerous alternative and supplemental approaches to antibiotic therapy for the prophylaxis and therapy of P. aeruginosa infections have been investigated. In particular, immunotherapeutic strategies focusing on the abrogation of one or more virulence factors associated with the pathogenesis of P. aeruginosa have been studied in animal models and have been investigated in human clinical trials as well (24) . While active or passive immunization targeting extracellular products, e.g., elastase, protease, and exotoxin A, has had limited success in prevention and treatment of P. aeruginosa infections in animal models (10, 39, 40) , similar therapies to stimulate or augment an antilipopolysaccharide (anti-LPS) immune response have been more effective (10, 11, 42, 46) . A significant drawback to anti-LPS immunotherapy, however, is the necessity to develop a multicomponent vaccine, immunoglobulin preparation, or monoclonal antibody (MAb) cocktail to provide protection against P. aeruginosa strains that characteristically express any one of at least 17 different serotypes of LPS (34) .
Studies in burn wound sepsis models (13, 36, 38) have indicated that motility is important to the virulence of P. aeruginosa. When burned mice were challenged with a motile, virulent strain of P. aeruginosa or its nonflagellated isogenic mutant, the number of bacteria required to provide a lethal dose with the isogenic mutant was approximately 104-fold greater than that with the motile parent strain (13, 38) . Moreover, results of murine burn wound sepsis model studies in which mice were . Motility of each bacterial isolate was assessed in motility agar by standard bacteriological technique (22) . Flagella were visualized by a rapid fuchsin stain of the bacteria performed as described by Forbes (19) .
Generation of antiflagellum MAbs. Female BALB/c mice (Fred Hutchinson Cancer Research Center), which were immunized to generate an immune response to a variety of P. aeruginosa antigens, were first injected intraperitoneally with viable P. aeruginosa IT-6 (8 x 106 organisms) (later shown to bear type b flagella), followed 2 weeks later with an injection of viable P. aeruginosa IT-5 (4 x 106 organisms), which was nonflagellated. During the following 2 weeks, the two strains were administered together in two weekly intraperitoneal injections. The dosage of each strain was increased for each immunization such that the final dose was 10-fold greater than the first dose. Four days after the last injection of viable bacteria, one mouse received a final intraperitoneal boost with a P. aeruginosa IT-6 outer membrane preparation (50 jig of protein) (21) . Three days after the last immunization the spleen was removed, and a fusion of spleen lymphocytes with NS-1 myeloma cells was performed as described by Tam et al. (50) .
Another group of BALB/c mice was injected intraperitoneally four times over a 6-week period with purified type a flagella (10 to 20 jig of protein) from IATS 6 and 8. Three days after the final boost, the spleen was removed from one animal and fused with NS-1 myeloma cells as described above.
Seven to ten days after plating of the fused cells, culture supernatants from each were assayed in an enzyme-linked immunosorbent assay (ELISA) as described below. Hybridomas producing anti-P. aeruginosa flagellum antibodies were then minicloned and cloned by limiting dilution techniques (50) . The isotypes of the antibodies were determined by ELISA, using the Mouse Monoclonal Sub-Isotyping Kit from American Qualex International, Inc., La Mirada, Calif.
Ascitic fluid containing MAb was prepared in BALB/c mice primed with pristane (2,6,10,14-tetramethylpentadecane; Aldrich Chemical Co., Milwaukee, Wis.) (50) . The concentration of MAb in the ascitic fluid was estimated by agarose gel electrophoresis (Paragon; Beckman Instruments, Inc., Brea, Calif.), using another purified murine MAb as a protein standard. All ascitic fluids that contained more than 5 mg of MAb per ml were pooled, divided into smaller samples, and frozen at -70°C. MAbs were purified from ascitic fluid by affinity chromatography on immobilized protein A (Pharmacia, Piscataway, N.J.) according to the method of Ey et al. (15) as modified by Seppala et al. (47) . Anti-P. aeruginosa LPS MAbs. Murine anti-P. aeruginosa LPS MAbs were prepared as described by Pennington et al. (42) . The following MAbs were included in assays: IIIH10 (IgG2a), anti-IT-1 LPS; VF5 (IgG2a), anti-IT-2 LPS; VF3 (IgG2b), anti-IT-3 LPS; and VD94 (IgG3), anti-IT-4 LPS.
ELISAs. Antigen plates for ELISAs were prepared either by binding viable bacteria to the wells of 96-well microtiter plates (Linbro, Flow Laboratories, Inc., McLean, Va.) coated with poly-L-lysine (PLL) (no. P-1524; Sigma, St. Louis, Mo.) (29) Before initiation of the ELISA procedure, nonspecific binding of antibodies was blocked with a 5% nonfat dry milk blocking buffer (27) 8.5) and then mixing the solution with 90 ml of glycerol (28) . Slides were viewed with a Leitz fluorescence microscope.
Purification of flagella. Flagella were isolated by differential centrifugation as described by Montie and co-workers (1, 37) , with the following modifications. Bacteria were harvested from 16-to 18-h TSB cultures (30°C), and shearing of the flagella from the bacteria was completed in 1 min. (51) . After transfer, the NCM was incubated in blocking buffer (see ELISA method described above) for 2 to 3 h. This step and all subsequent steps were performed at room temperature with rocking agitation of the NCM. After blocking, the NCM was washed with 0.05% (vol/vol) Tween 20 in PBS (PBS-Tween) (6) . Purified MAb (10 ,ug/ml in PBS-Tween) was then incubated with the NCM for 1 h. After washing of the NCM as described above, alkaline phosphatase-conjugated goat anti-mouse IgG plus IgM (Tago, Inc.), diluted as specified by the manufacturer in PBS-Tween, was incubated with the NCM for 1 h. The NCM was washed as before, and bromochloroindolyl phosphateNitro Blue Tetrazolium substrate (33) was added for 15 min. The reaction was terminated by washing the NCM with distilled water.
Agglutination. Bacteria for agglutination assays were grown for 16 to 18 h at 37°C on TSA plates and then suspended in PBS to concentrations of 0.5 and 1.0 OD660
units. Purified MAbs were diluted in PBS to concentrations of 100, 10, and 1 p.g/ml. Equal volumes of a bacterial suspension and MAb dilution were combined, immediately placed on a microscope slide, covered with a cover slip, and viewed by light microscopy (10OX magnification).
Motility inhibition assay. In 10-cm plastic culture dishes, an underlayer (6 ml) of 0.6% (wt/vol) agar in motility culture broth (MCB) (1% [wt/vol] Casitone, 0.3% [wt/vol] yeast extract, 0.5% [wt/vol] NaCI) was poured and allowed to solidify for approximately 30 min. Meanwhile, purified MAb was diluted in MCB to a concentration of 80,ug/ml and then titrated in fourfold serial dilutions such that the lowest concentration was 0.02 ,ug/ml. The final volume of MCB containing MAb was 6 ml for the five highest concentrations and was 18 ml for the two lowest concentrations and for a sample without MAb.
Bacteria grown at 37°C to mid-log phase in MCB were diluted to an OD660 of 0.2. The suspension was further diluted 10-6 in MCB, and a 10-,ul sample was added to the MCB tubes containing antibody and to the tube containing broth without antibody to provide 5 to 20 CFU per tube. Immediately after addition of the organisms to the MCB, an equal volume of MCB containing 0.6% (wt/vol) agar and 0.4% (wt/vol) sodium nitrate was added to the tubes to achieve final concentrations of 0.3% (wt/vol) agar and 0.2% (wt/vol) sodium nitrate (43) and final MAb concentrations ranging from 40 to 0.01 ,ug/ml. Each culture was gently mixed and then poured onto the solidified agar underlayer.
One 10-cm assay plate was prepared for the five highest MAb concentrations, and three plates were prepared for each of the two lowest concentrations and for the control without antibody.
After this layer had solidified (approximately 30 min), it was overlaid with 0.6% (wt/vol) agar in MCB (6 ml Mouse burn wound sepsis model. The burn wound sepsis model was performed basically as described by Collins and Roby (8) , with the following modifications. At least 1 day but less than 1 week before an experiment, female SwissWebster mice (Simonsen Laboratories, Gilroy, Calif.) weighing 24 to 26 g were depiliated as follows. Mice were first anesthetized by intramuscular injection (0.1 ml in each thigh) of a mixture of xylazine (Mobay Corp., Shawnee, Kans.) (20 mg/kg of body weight) and ketamine hydrochloride (Parke-Davis, Morris Plains, N.J.) (1 mg/kg). The right side of each mouse was shaved and then treated with a depilatory agent (Nair; Carter-Wallace Corp., New York, N.Y.) for 3 to 5 min to effectively remove all hair from the shaved area.
Burns were administered to mice after the animals were anesthetized as described above. A woven silicon cloth template (Zetex cloth; 260 by 260 mm; NEWTEX Corp., Vector, N.Y.), with a rectangle (15 by 30 mm) cut from the center of the cloth was used to contain the area of the burn to approximately 5.5 to 6.0% of the body surface (20) . Each mouse was laid left side down in a laminar flow hood, and the template was placed over the right side such that the open rectangle was centered between the forelimb and hindlimb and between the dorsal and ventral midlines.
The burn was administered with a grid-top adjustable flame gas burner to which a halo support was attached to aid in positioning the burner at a constant distance, approximately 1.5 cm, from the skin. The flame was applied until the skin just began to blanch, approximately 3 to 5 s. Immediately after removal of the flame, mice were injected subeschar with 0.5 ml of the challenge inoculum. Control animals received cold diluent only. All animals were checked daily for 10 to 14 days for symptoms and mortality. Obviously terminal (moribund) animals were euthanized.
Histopathological examination of the burn site indicated that a full-thickness, third-degree burn was achieved over the entire area of the template opening, with a sharp margin around the burn area. The burn was characterized by destruction of the epidermis, dermal appendages, epithelial (16) of mortality data at day 10 for groups of mice that were challenged with increasing two-or fourfold doses of bacteria. For the prophylactic experiments, the challenge dose of each bacterial strain was approximately 10 LD50s, which resulted in 80 to 90% mortality of animals in the negative control groups. The dose was increased to 1,000 LD50s for the therapeutic studies to consistently provide greater than 95% mortality in the negative control groups. RESULTS Isolation of antiflagelium monoclonal antibodies. A fusion of NS-1 myeloma cells and spleen cells from a mouse immunized with viable bacteria (IT-5 and IT-6) and outer membrane preparations (IT-6) was first assayed by ELISA on each of the four P. aeruginosa reference strains IT-1, IT-2, IT-3, and IT-4. Since the objective of the fusion was to generate anti-P. aeruginosa cross-reactive antibodies, four strains other than those used for immunizations were chosen for the initial screen. Master wells containing antibody that bound to any of the four strains were then assayed in a second ELISA in which the individual IATS reference strains 1 to 12 were treated with Formalin and adhered to microtiter wells. Antibody present in one master well, IVE8, which bound only to IT-2 in the first assay, bound to IATS 2, 3, 4, 5, 7, 10, 11, and 12, all of which have type b flagella (4, 5) . The IVE8 antibody was therefore presumptively identified as an anti-type b flagellum antibody. This information also suggested that IT-2 had type b flagella. The IVE8 cell line was cloned by limiting dilution techniques, and ascitic fluid was prepared as described in Materials and Methods. The isotype of the IVE8 MAb was shown to be IgG2a.
Isolation of an antibody that bound to flagellum type b IATS strains was rare from this fusion and similar fusions in which mice were immunized with viable organisms, likely because of exposure of the mice to more immunodominant antigens, e.g., LPS. Only one other master well contained anti-flagellum type b antibody, but the cell line was not cloned because it was unstable. To more readily generate anti-flagellum type a MAbs, mice were immunized with purified type a flagella, and splenocytes from an animal were fused with NS-1 myeloma cells. The fusion was initially screened by ELISA in which binding of antibody present in culture supernatants to P. aeruginosa reference strains IATS 6, IATS 9, and IT-1 was measured and compared. IATS 6 and 9 are type a flagellated organisms (4, 5) , and IT-1 is nonflagellated, as demonstrated by fuchsin dye staining (data not shown). Only those hybridomas producing antibody that bound to the type a flagellated bacteria and not to strain IT-1 were analyzed further by an ELISA with IATS 1 to 12. Several master wells contained antibody that bound to the type a strains, IATS 1, 6, 8, and 9 (4, 5), and not to the type b strains. The cell line designated IIG5 from one fusion was cloned, and ascitic fluid was prepared. The isotype of the IIG5 MAb was shown to be IgG3. Antibodies produced by the cloned IVE8 and IIG5 cell lines had reactivity patterns on the IATS strains identical to those described for the master wells.
Indirect immunofluorescence assays. Immunofluorescence studies demonstrated that IIG5 and IVE8 bound to the flagella of P. aeruginosa strains. A fluorescence pattern of short sinuous lines similar to the shape of flagella observed by fuchsin dye staining was observed when IIG5 was incubated with strain IATS 1 and when IVE8 was incubated with strain IT-2 ( Fig. 1A and E) . The reactions were specific, since IIG5 did not bind to strain IT-2 and IVE8 did not bind to IATS 1 ( Fig. 1D and H) . To visualize the flagella in relation to the whole organism, specific anti-P. aeruginosa LPS murine MAbs VD94 and VF5, which bound to the outer cell membrane of the IATS 1 and IT-2 strains, respectively (Fig. 1B and F) , were incorporated into the assay. Inclusion of the specific anti-LPS MAb with IIG5 or IVE8 showed the outline of the bacterium with a flagellum attached at a polar position characteristic of P. aeruginosa ( Fig. 1C and G) .
Immunoblot analysis. Flagellin, the protein subunit that constitutes the flagellum organelle, was identified as the target antigen of the MAbs by immunoblot analysis. Flagella isolated from P. aeruginosa reference strains IATS 6, IATS 8, and IT-2 were separated by SDS-PAGE under reducing conditions and visualized in the gel by staining with Coomassie blue (Fig. 2A) . The molecular masses of the major band from the IATS 6 and IATS 8 flagellum preparations were 41,800 and 40,600 Da, respectively, and the molecular mass of the major band from the IT-2 flagellum preparation was 48,500 Da. Molecular masses of all flagellins were lower than those previously reported, 45,000 and 47,000 Da for type a flagellins from IATS 6 and IATS 8, respectively, and 53,000 Da for flagellin from type b flagella (1) . The difference in the molecular masses reported here and by Allison et al. (1) is likely due to differences in migration of proteins in a gradient gel compared with a fixed-percentage acrylamide gel. Other experiments in our laboratory in which flagellin from IT-2 was separated in a 10% acrylamide gel (30) showed that the molecular weight of the type b flagellin band was 53,000 (unpublished observations), similar to values in other published reports.
The identity of the low-molecular-weight contaminants present in the IATS 6 flagellum preparation (Fig. 2A, lane 2) is unknown but could represent degradation products of flagellin. Alternatively, one or both of the protein bands might represent pilus contamination, since the molecular mass of each contaminant in the flagellum preparation is similar to that reported for pilin (15,000 Da) (45) .
All three flagellum preparations from a gel identical to the one stained with Coomassie blue were transferred to an NCM and immunoblotted. IIG5 bound to the flagellin of both type a strains but not to the type b flagellin of IT-2 (Fig. 2B) , while IVE8 bound to flagellin of the type b strain but not to the flagellins of either type a strain (Fig. 2C) . If the lowmolecular-weight contaminants present in the IATS 6 preparation were degradation products of flagellin, the fragments did not include the epitope recognized by IIG5, since the MAb did not identify the bands in the immunoblot.
Flagellum typing of P. aeruginosa reference strains and clinical isolates. Binding of IIG5 and IVE8 to each of the 17 IATS reference strains was analyzed by ELISA. As observed in the initial assays, IIG5 bound specifically to the type a-bearing strains, IATS 1, 6, 8, and 9 (4, 5), and IVE8 was specific for the type b strains, IATS 2, 3, 4, 5, 7, 10, 11, ,ug/ml) were combined with bacteria (0.5 OD660 unit), motile bacteria were not observed. Some bacteria had tethered and a few small clumps of bacteria were seen, but the majority of the organisms were single without directed motion. The lack of motility of the bacteria was easily distinguished from the quick darting movement of organisms in the presence of the nonspecific antiflagellum MAb at 100 ,ug/ml. Similar observations were made with the higher concentration of bacteria Fig.  3A and B, respectively. In the absence of specific MAb, the bacteria were freely motile and were able to penetrate the soft agar. Little difference in migration inhibition of 1624 by 1IG5 at concentrations of 10 and 40 ,ug/ml was observed, indicating that 1IG5 concentrations of 10 ,ug/ml and greater provided maximal inhibition of migration of 1624. Maximum inhibition of migration of F164 by IVE8 was achieved at MAb concentrations of 2.5 ,ug/ml and greater. All isolates recognized by 1IG5 or IVE8 by ELISA that have been tested in this assay have been inhibited by the specific MAb. Furthermore, inhibition of motility of type a isolates by IVE8 or inhibition of motility of type b isolates by IIG5 has never been observed.
Prophylactic protection studies. The protective efficacy of the antiflagellum MAbs was studied in a mouse burn wound sepsis model. For these studies, purified MAbs were administered intravenously 1 to 2 h before administration of the burn and challenge with approximately 10 LD50s of P. aeruginosa (Table 3 ). In the first study, mice were challenged with the P. aeruginosa clinical isolate G98 (IT-3 LPS), which bears type a flagella. All animals that received IIG5 survived, while only 20% of those that received the negative control MAb, anti-IT-1 LPS MAb (IIIH10), lived. In a second experiment, in which mice were challenged with another type a isolate, PA220 (IT-1 LPS), the specific MAb 11G5 again provided significant protection, whereas the (40 ,ug) diluted in PBS were administered intravenously in a total volume of 0.2 ml 1 to 2 h before burn and bacterial challenge.
b Number of animals alive at 10 days compared with the number of animals in each group.
Significance of protection was determined by the Fisher exact test, companng survival with that of the nonspecific MAb control (-) . P values of greater than 0.05 were not significant (NS). antiflagellum type b MAb and negative control anti-LPS MAb (VF3, anti-IT-3 LPS) were not protective. Significant protection by IVE8 of mice challenged with the flagellum type b-bearing P. aeruginosa IT-2 reference strain was demonstrated in a third study. The specificity of the antiflagellum MAbs was again observed, as IIG5 did not protect animals challenged with IT-2.
Therapeutic protection study. To assess the therapeutic efficacy of the antiflagellum MAbs, administration of the antibodies was delayed for various times postchallenge. Bacterial strains other than those used in the prophylactic studies were chosen to show that protection was not strain dependent. Animal groups were challenged with 1,000 LD50s (20,000 CFU) of the clinical isolate 1624 (IT-2 LPS) bearing type a flagella. Purified IIG5 was administered intraperitoneally at a dose of 50, 10, or 2 ,ug per mouse at 1, 7, or 20 h after burn and challenge. In a similar manner, burned mice were challenged with 1,000 LD50s (3,000 CFU) of a type b flagellum-bearing isolate, F164 (IT-4 LPS), followed by administration of IVE8. As a negative control for each study, the irrelevant antiflagellum MAb was administered at a dose of 50 jig per mouse at the 1-h time point.
The results of the studies are presented in Fig. 4 and 5.
Administration of IIG5 at 50-and 10-p,g doses at 1 h and 7 h postchallenge protected 70 to 90% of the animals. Similarly, 50 and 10 postchallenge resulted in significant mortality (0 to 10% survival). By 16 h after challenge with this highly lethal dose of bacteria, the mice usually had a systemic infection (unpublished observation) and unprotected animals died within the next 24 h. Even though treatment with antiflagellum MAbs as late as 20 h after bacterial challenge did not result in significant survival of animals, the higher doses did prolong the time until death. Administration of 50 and 10 ,ug of IVE8 to mice challenged with F164 extended survival of animals (P < 0.001 and P < 0.01, respectively), as did treatment with 50 ,ug of TIG5 for animals challenged with 1624 (P < 0.01) (35) .
DISCUSSION
Two anti-P. aeruginosa flagellum murine MAbs, 11G5, specific for type a flagella, and IVE8, specific for type b (25) and passive immunization with rabbit antiflagellum antisera (12) .
Of particular interest was the potential value of anti-P. aeruginosa flagellum MAbs in treatment of an infected host. A therapeutic study was performed in which three different doses of specific MAb were administered at various times after burn and challenge. Significant protection was dependent on dose and the time at which the specific MAb was administered. Significant survival of animals challenged with 1,000 LD50s of P. aeruginosa strains was observed when the specific MAb at doses of 10 and 50 ,ug per animal was administered as late as 7 h after burn and challenge. Delaying administration of MAb until 20 h after burn and challenge, when the mice were septic, resulted in prolonged survival of animals receiving the higher concentrations of MAb but could not prevent death of the animals. As with any antiinfective therapy, early intervention with MAbs appeared critical to a favorable outcome.
Host defense against P. aeruginosa infections is believed to rely on phagocytosis of the organisms by host polymorphonuclear leukocytes in the presence of heat-labile opsonins and heat-stable antibodies (53), primarily type-specific LPS antibodies (52) . These observations raise interesting questions regarding the mechanism of protection by antiflagellum antibodies, since binding of antiflagellum antibodies to a bacterium conceivably would not result in sufficient opsonization of the organism such that phagocytosis could be induced. Anderson and Montie (2, 3) have shown that phagocytosis of P. aeruginosa by mouse peritoneal polymorphonuclear leukocytes was greater in vitro in the presence of antiflagellum rabbit antisera than in the presence of normal rabbit sera. Preliminary experiments in our laboratory indicated that opsonophagocytosis by the antiflagellum MAbs did occur, but the efficiency of opsonization varied according to the bacterial isolate used in the assay. Furthermore, opsonophagocytic activity of the antiflagellum MAbs was far inferior to that of specific anti-LPS MAbs (unpublished observation), which are very efficient opsonins (48, 49) . The fact that antiflagellum MAbs were less effective opsonins than anti-LPS MAbs does not preclude the possibility that opsonization of bacteria by antiflagellum antibodies is involved in prevention of lethal infection. Additional in vitro and in vivo studies may clarify the role that opsonization by antiflagellum antibodies plays in protection.
The possibility that antiflagellum antibodies protected infected animals by bactericidal or bacteriostatic activity was discounted by results of in vitro studies. Omission of polymorphonuclear leukocytes in opsonization assay controls demonstrated that the MAbs did not have bactericidal or bacteriostatic activity in the presence or absence of complement (unpublished observations). Drake and Montie (12) also demonstrated lack of bactericidal or bacteriostatic activity of antiflagellum antisera.
The primary mechanism proposed by which antiflagellum antibodies protect animals in the burn wound sepsis model is by inhibiting the motility of bacteria, thereby sequestering the infection to the burn site (13, 25, 26) . This conclusion was suggested in part by the importance of motility to the pathogenesis of P. aeruginosa in burn wound sepsis models (13, 36, 38) . The role of motility inhibition of P. aeruginosa in burn wound infections was more directly addressed by Drake and Montie (13) , who examined dissemination of P. aeruginosa in a mouse burn wound sepsis model. They found that a mutant lacking flagella was unable to disseminate from the burn wound site. Moreover, dissemination of the parent flagellated strain to the liver or blood of animals treated with antiflagellum antisera before challenge was also significantly reduced. Since the only known difference between the mutant strain and the parent was the loss of flagella, and since dissemination of the parent strain in the presence of antiflagellum sera was like that observed with the mutant in untreated animals, the loss of virulence of the parent flagellated strain was attributed to inhibition of motility by the antiflagellum antisera.
The phenomenon of motility inhibition of P. aeruginosa by antiflagellum antibodies has been observed in vitro in soft agar assays with antiflagellum antisera (12, 23) and with antiflagellum MAbs (Fig. 3) . P. aeruginosa strains that were used in the therapeutic protection studies were inhibited in a dose-dependent manner by the specific MAb in the soft agar assay. The minimum concentration of IIG5 required to provide maximum inhibition of migration of the type a flagellated strain was 10 ,ug/ml. Less IVE8, 2.5 ,ug/ml, was required to provide maximum inhibition of the type b flagellated strain. Additional studies are required to determine whether a correlation exists between in vitro motility inhibition and in vivo protective efficacy.
Agglutination of bacteria by antiflagellum antisera has been observed (12, 23) and suggested as the means of motility inhibition (12) . We have shown in this study that binding of specific antiflagellum MAb at concentrations of 10 and 100 ,ug/ml to bacteria (1.0 OD6. unit) resulted in agglutination of a portion of the population. Moreover, organisms not incorporated into clumps were nonmotile, devoid of any directed motion. At the lower concentration of bacteria (0.5 OD660 unit) agglutination was rare, but loss of motility was still observed. This finding suggests that binding of antiflagellum antibodies to bacteria inhibits motility, not only by agglutination of several bacteria but also by directly affecting the motility of a single organism.
The usefulness of antiflagellum MAbs for immunotherapy depends on the potential of the MAbs for treating infection by a majority of P. aeruginosa strains. Analysis of the cross-reaction of the anti-type a MAb, IIG5, in particular, with a large sample of strains was important because type a flagella have been defined as serologically complex (4 (4, 5, 31) suggest that two antiflagellum MAbs could be used to treat infection caused by the vast majority of P. aeruginosa strains. Even though other anti-P. aeruginosa MAbs, in particular anti-LPS MAbs, have been prepared and shown to be protective in animal models (10, 42, 46) , to approach the clinical coverage that two antiflagellum MAbs offer could require as many as 17 anti-LPS MAbs. The preparation of such a cocktail for clinical administration would be a formidable task. Hence, current efforts in the laboratory are directed toward development of human anti-P. aeruginosa flagellum MAbs. ACKNOWLEDGMENTS We thank R. Darveau and H. Raff for critical review of the manuscript. Special recognition is given to Gary Keizur, Cara Watkins, and Grace Maloney for performance of the animal protection studies. We thank Dennis Hanson and Glenna Lynch for their technical assistance. We are indebted to the Infectious Disease Therapeutics Biological Resources group for their bacteriology expertise and assistance.
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